Takaisin Tulosta

Psoriaasi ja nivelpsoriaasi, näytönastekatsausten kirjallisuusviitteet

Lisätietoa aiheesta
Käypä hoito -toimitus
25.10.2021

Kirjallisuusviiteluettelosta löytyy koottuna Käypä hoito -suosituksen Psoriaasi ja nivelpsoriaasi «Psoriaasi ja nivelpsoriaasi»1 näytönastekatsauksissa arvioitu kirjallisuus

Kirjallisuutta

  1. Ahlehoff O, Gislason GH, Charlot M ym. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147-57 «PMID: 21114692»PubMed
  2. Antoni C, Krueger GG, de Vlam K ym. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7 «PMID: 15677701»PubMed
  3. Asaduzzaman AT, Sikder A, Mahmud MM ym. Efficacy and safety of leflunomide in psoriatic arthritis. J Pakistan Assoc Dermatol 2014;24:51-6
  4. Asahina A, Nakagawa H, Etoh T ym. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010;37:299-310 «PMID: 20507398»PubMed
  5. Attia A, Abushouk AI, Ahmed H ym. Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Clin Drug Investig 2017;37:439-451 «PMID: 28197901»PubMed
  6. Augustin M, Reich K, Glaeske G ym. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147-51 «PMID: 20169297»PubMed
  7. Bachelez H, van de Kerkhof PC, Strohal R ym. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015;386:552-61 «PMID: 26051365»PubMed
  8. Baraliakos X, Gossec L, Pournara E ym. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021;80:582-590 «PMID: 33334727»PubMed
  9. Barker J, Hoffmann M, Wozel G ym. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011;165:1109-17 «PMID: 21910713»PubMed
  10. Bavinck JN, Tieben LM, Van der Woude FJ ym. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-8 «PMID: 7636533»PubMed
  11. Behrens F, Finkenwirth C, Pavelka K ym. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 2013;65:464-70 «PMID: 23042698»PubMed
  12. Bilal J, Berlinberg A, Bhattacharjee S ym. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat 2018;29:569-578 «PMID: 29532693»PubMed
  13. Bingham SJ, Buch MH, Lindsay S ym. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003;42:1009-10 «PMID: 12869673»PubMed
  14. Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg 2008;12:230-4 «PMID: 18845092»PubMed
  15. Blauvelt A, Reich K, Papp KA ym. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol 2018;179:615-622 «PMID: 29742274»PubMed
  16. Blauvelt A, Reich K, Tsai TF ym. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76:60-69.e9 «PMID: 27663079»PubMed
  17. Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7 «PMID: 11886519»PubMed
  18. Braun J, Kästner P, Flaxenberg P ym. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81 «PMID: 18163521»PubMed
  19. Brune A, Miller DW, Lin P ym. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007;24:76-80 «PMID: 17300658»PubMed
  20. Bykerk VP, Akhavan P, Hazlewood GS ym. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559-82 «PMID: 21921096»PubMed
  21. Cameron H, Dawe RS, Yule S ym. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002;147:973-8 «PMID: 12410709»PubMed
  22. Chaudhari U, Romano P, Mulcahy LD ym. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7 «PMID: 11410193»PubMed
  23. Clegg DO, Reda DJ, Mejias E ym. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20 «PMID: 8961906»PubMed
  24. Cohen SB, van Vollenhoven RF, Winthrop KL ym. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 2020;: «PMID: 33115760»PubMed
  25. Combe B, Goupille P, Kuntz JL ym. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996;35:664-8 «PMID: 8670601»PubMed
  26. Darley CR, Cunliffe WJ, Green CM ym. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 1996;135:390-3 «PMID: 8949431»PubMed
  27. Dawe RS, Wainwright NJ, Cameron H ym. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833-9 «PMID: 9666830»PubMed
  28. de Korte J, van der Valk PG, Sprangers MA ym. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol 2008;158:375-81 «PMID: 18067483»PubMed
  29. Deodhar A, Gottlieb AB, Boehncke WH ym. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2018;391:2213-2224 «PMID: 29893222»PubMed
  30. Deodhar A, Helliwell PS, Boehncke WH ym. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFa inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1115-1125 «PMID: 32178765»PubMed
  31. Douglas WS, Poulin Y, Decroix J ym. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5 «PMID: 12125943»PubMed
  32. Ellis CN, Fradin MS, Messana JM ym. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84 «PMID: 1986287»PubMed
  33. Farr M, Kitas GD, Waterhouse L ym. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9 «PMID: 1968355»PubMed
  34. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992;326:1654-60 «PMID: 1588978»PubMed
  35. Fleming C, Ganslandt C, Guenther L ym. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010;20:465-71 «PMID: 20413372»PubMed
  36. Flytström I, Stenberg B, Svensson A ym. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21 «PMID: 17986302»PubMed
  37. Freeman AK, Linowski GJ, Brady C ym. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-8 «PMID: 12664020»PubMed
  38. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237-42 «PMID: 10233215»PubMed
  39. Gelfand JM, Dommasch ED, Shin DB ym. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-8 «PMID: 19458634»PubMed
  40. Gelfand JM, Neimann AL, Shin DB ym. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41 «PMID: 17032986»PubMed
  41. Gelfand JM, Shin DB, Neimann AL ym. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201 «PMID: 16741509»PubMed
  42. Gladman D, Fleischmann R, Coteur G ym. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) 2014;66:1085-92 «PMID: 24339179»PubMed
  43. Gladman D, Rigby W, Azevedo VF ym. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med 2017;377:1525-1536 «PMID: 29045207»PubMed
  44. Gladman DD, Mease PJ, Ritchlin CT ym. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88 «PMID: 17265483»PubMed
  45. Gniadecki R, Bang B, Bryld LE ym. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015;172:244-52 «PMID: 25132294»PubMed
  46. Gniadecki R, Kragballe K, Dam TN ym. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091-6 «PMID: 21219290»PubMed
  47. Goldfarb MT, Ellis CN, Gupta AK ym. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988;18:655-62 «PMID: 2967310»PubMed
  48. Gollnick H, Bauer R, Brindley C ym. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988;19:458-68 «PMID: 2971692»PubMed
  49. Gordon K, Papp K, Poulin Y ym. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012;66:241-51 «PMID: 21752491»PubMed
  50. Gordon KB, Blauvelt A, Papp KA ym. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med 2016;375:345-56 «PMID: 27299809»PubMed
  51. Gordon KB, Duffin KC, Bissonnette R ym. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med 2015;373:136-44 «PMID: 26154787»PubMed
  52. Gordon KB, Langley RG, Leonardi C ym. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606 «PMID: 17010738»PubMed
  53. Gordon KB, Strober B, Lebwohl M ym. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018;392:650-661 «PMID: 30097359»PubMed
  54. Gordon PM, Diffey BL, Matthews JN ym. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32 «PMID: 10534635»PubMed
  55. Gottlieb AB, Blauvelt A, Thaçi D ym. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018;79:302-314.e6 «PMID: 29660421»PubMed
  56. Gottlieb AB, Evans R, Li S ym. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42 «PMID: 15389187»PubMed
  57. Gottlieb AB, Leonardi C, Kerdel F ym. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:652-60 «PMID: 21574983»PubMed
  58. Gottlieb AB, Matheson RT, Lowe N ym. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32; discussion 1632 «PMID: 14676082»PubMed
  59. Gribetz C, Ling M, Lebwohl M ym. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-8 «PMID: 15523351»PubMed
  60. Griffiths CE, Reich K, Lebwohl M ym. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386:541-51 «PMID: 26072109»PubMed
  61. Griffiths CE, Strober BE, van de Kerkhof P ym. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28 «PMID: 20071701»PubMed
  62. Hannuksela-Svahn A, Pukkala E, Läärä E ym. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90 «PMID: 10692122»PubMed
  63. Heydendael VM, Spuls PI, Opmeer BC ym. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65 «PMID: 12917302»PubMed
  64. Hoekstra M, Haagsma C, Neef C ym. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645-8 «PMID: 15088287»PubMed
  65. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70 «PMID: 2527051»PubMed
  66. Inzinger M, Wippel-Slupetzky K, Weger W ym. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol 2016;96:207-12 «PMID: 26271044»PubMed
  67. Jacobi A, Braeutigam M, Mahler V ym. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008;216:133-6 «PMID: 18216475»PubMed
  68. Kadakia KC, Barton DL, Loprinzi CL ym. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 2012;118:2128-37 «PMID: 21882176»PubMed
  69. Kaltwasser JP, Nash P, Gladman D ym. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50 «PMID: 15188371»PubMed
  70. Kavanaugh A, Antoni CE, Gladman D ym. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43 «PMID: 16439444»PubMed
  71. Kavanaugh A, Krueger GG, Beutler A ym. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505 «PMID: 17114188»PubMed
  72. Kavanaugh A, McInnes I, Mease P ym. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86 «PMID: 19333944»PubMed
  73. Kavanaugh A, McInnes IB, Krueger GG ym. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2013;65:1666-73 «PMID: 23666608»PubMed
  74. Kavanaugh A, McInnes IB, Mease P ym. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 2014;73:1689-94 «PMID: 24748630»PubMed
  75. Kavanaugh A, McInnes IB, Mease PJ ym. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-85 «PMID: 23161902»PubMed
  76. Kavanaugh A, Ritchlin C, Rahman P ym. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6 «PMID: 24553909»PubMed
  77. Kavanaugh A, van der Heijde D, McInnes IB ym. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17 «PMID: 22378566»PubMed
  78. Kimball AB, Gordon KB, Fakharzadeh S ym. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-72 «PMID: 22356258»PubMed
  79. Kimball AB, Papp KA, Wasfi Y ym. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-45 «PMID: 23279003»PubMed
  80. Kirke SM, Lowder S, Lloyd JJ ym. A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol 2007;127:1641-6 «PMID: 17380117»PubMed
  81. Kleinpenning MM, Smits T, Boezeman J ym. Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens. Br J Dermatol 2009;161:1351-6 «PMID: 19466961»PubMed
  82. Kragballe K, Austad J, Barnes L ym. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60 «PMID: 16704648»PubMed
  83. Kragballe K, Hoffmann V, Ortonne JP ym. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009;161:159-66 «PMID: 19416259»PubMed
  84. Kragballe K, Noerrelund KL, Lui H ym. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-73 «PMID: 15214905»PubMed
  85. Kreuter A, Sommer A, Hyun J ym. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-43 «PMID: 16983001»PubMed
  86. Laburte C, Grossman R, Abi-Rached J ym. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130:366-75 «PMID: 8148280»PubMed
  87. Landells I, Marano C, Hsu MC ym. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015;73:594-603 «PMID: 26259989»PubMed
  88. Langley RG, Elewski BE, Lebwohl M ym. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 2014;371:326-38 «PMID: 25007392»PubMed
  89. Langley RG, Lebwohl M, Krueger GG ym. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 2015;172:1371-83 «PMID: 25307931»PubMed
  90. Lassus A, Geiger JM, Nyblom M ym. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol 1987;117:333-41 «PMID: 2890369»PubMed
  91. Laws PM, Downs AM, Parslew R ym. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol 2012;166:189-95 «PMID: 21929536»PubMed
  92. Lebwohl M, Blauvelt A, Paul C ym. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol 2018;79:266-276.e5 «PMID: 29660425»PubMed
  93. Lebwohl M, Freeman AK, Chapman MS ym. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-30 «PMID: 15523350»PubMed
  94. Leenutaphong V, Nimkulrat P, Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 2000;16:202-6 «PMID: 11068858»PubMed
  95. Leonardi CL, Kimball AB, Papp KA ym. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74 «PMID: 18486739»PubMed
  96. Leonardi CL, Powers JL, Matheson RT ym. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22 «PMID: 14627786»PubMed
  97. Liao YH, Chiu HC, Tseng YS ym. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007;157:1005-12 «PMID: 17935517»PubMed
  98. Lie E, van der Heijde D, Uhlig T ym. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671-6 «PMID: 19740904»PubMed
  99. Lindelöf B, Sigurgeirsson B, Tegner E ym. PUVA and cancer: a large-scale epidemiological study. Lancet 1991;338:91-3 «PMID: 1676477»PubMed
  100. López-Ferrer A, Vilarrasa E, Gich IJ ym. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol 2013;169:1141-7 «PMID: 23909993»PubMed
  101. Luger TA, Cambazard F, Larsen FG ym. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321-8 «PMID: 18787325»PubMed
  102. Mahrle G, Schulze HJ, Färber L ym. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88 «PMID: 7822521»PubMed
  103. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042-5 «PMID: 11589933»PubMed
  104. Maza A, Montaudié H, Sbidian E ym. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol 2011;25 Suppl 2:19-27 «PMID: 21388455»PubMed
  105. McInnes IB, Anderson JK, Magrey M ym. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med 2021;384:1227-1239 «PMID: 33789011»PubMed
  106. McInnes IB, Kavanaugh A, Gottlieb AB ym. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9 «PMID: 23769296»PubMed
  107. McInnes IB, Mease PJ, Kirkham B ym. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46 «PMID: 26135703»PubMed
  108. Mease P, Deodhar A, Fleischmann R ym. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 2015;1:e000119 «PMID: 26509074»PubMed
  109. Mease P, Genovese MC, Gladstein G ym. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48 «PMID: 21128258»PubMed
  110. Mease P, Hall S, FitzGerald O ym. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 2017;377:1537-1550 «PMID: 29045212»PubMed
  111. Mease P, van der Heijde D, Landewé R ym. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018;77:890-897 «PMID: 29550766»PubMed
  112. Mease PJ, Fleischmann R, Deodhar AA ym. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48-55 «PMID: 23942868»PubMed
  113. Mease PJ, Gladman DD, Collier DH ym. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol 2019;71:1112-1124 «PMID: 30747501»PubMed
  114. Mease PJ, Gladman DD, Gomez-Reino JJ ym. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatol 2020;2:459-470 «PMID: 32710493»PubMed
  115. Mease PJ, Gladman DD, Ritchlin CT ym. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89 «PMID: 16200601»PubMed
  116. Mease PJ, Goffe BS, Metz J ym. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90 «PMID: 10972371»PubMed
  117. Mease PJ, Gottlieb AB, van der Heijde D ym. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 2017;76:1550-1558 «PMID: 28473423»PubMed
  118. Mease PJ, Helliwell PS, Hjuler KF ym. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis 2021;80:185-193 «PMID: 33106286»PubMed
  119. Mease PJ, Kivitz AJ, Burch FX ym. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21 «PMID: 16463435»PubMed
  120. Mease PJ, Kivitz AJ, Burch FX ym. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72 «PMID: 15248226»PubMed
  121. Mease PJ, Lertratanakul A, Anderson JK ym. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2020;: «PMID: 33272960»PubMed
  122. Mease PJ, McInnes IB, Kirkham B ym. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015;373:1329-39 «PMID: 26422723»PubMed
  123. Mease PJ, Rahman P, Gottlieb AB ym. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1126-1136 «PMID: 32178766»PubMed
  124. Mease PJ, Smolen JS, Behrens F ym. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020;79:123-131 «PMID: 31563894»PubMed
  125. Mease PJ, van der Heijde D, Ritchlin CT ym. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 2017;76:79-87 «PMID: 27553214»PubMed
  126. Mehta NN, Azfar RS, Shin DB ym. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-6 «PMID: 20037179»PubMed
  127. Menter A, Feldman SR, Weinstein GD ym. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1-15 «PMID: 17097378»PubMed
  128. Menter A, Tyring SK, Gordon K ym. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15 «PMID: 17936411»PubMed
  129. Menter A, Tyring SK, Gordon K ym. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15 «PMID: 17936411»PubMed
  130. Nash P, Kirkham B, Okada M ym. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017;389:2317-2327 «PMID: 28551073»PubMed
  131. Nash P, Mease PJ, McInnes IB ym. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018;20:47 «PMID: 29544534»PubMed
  132. Nash P, Ohson K, Walsh J ym. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 2018;77:690-698 «PMID: 29343507»PubMed
  133. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003;49:644-50 «PMID: 14512910»PubMed
  134. Norsgaard H, Kurdykowski S, Descargues P ym. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res 2014;306:719-29 «PMID: 25027750»PubMed
  135. Ohtsuki M, Fujita H, Watanabe M ym. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. J Dermatol 2019;46:686-694 «PMID: 31237727»PubMed
  136. Oranje AP, Marcoux D, Svensson A ym. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997;36:203-8 «PMID: 9039169»PubMed
  137. Paller AS, Siegfried EC, Eichenfield LF ym. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010;63:762-8 «PMID: 20605256»PubMed
  138. Paller AS, Siegfried EC, Langley RG ym. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-51 «PMID: 18199863»PubMed
  139. Paller AS, Siegfried EC, Pariser DM ym. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol 2016;74:280-7.e1-3 «PMID: 26775775»PubMed
  140. Papp K, Reich K, Leonardi CL ym. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015;73:37-49 «PMID: 26089047»PubMed
  141. Papp KA, Guenther L, Boyden B ym. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54 «PMID: 12522370»PubMed
  142. Papp KA, Langley RG, Lebwohl M ym. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84 «PMID: 18486740»PubMed
  143. Papp KA, Merola JF, Gottlieb AB ym. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol 2018;79:277-286.e10 «PMID: 29609013»PubMed
  144. Papp KA, Poulin Y, Bissonnette R ym. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012;66:e33-45 «PMID: 20850895»PubMed
  145. Papp KA, Tyring S, Lahfa M ym. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12 «PMID: 15948997»PubMed
  146. Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol 1999;16:321-5 «PMID: 10469423»PubMed
  147. Patrizi A, Neri I, Rizzoli L ym. Topical calcipotriol in childhood psoriasis. Acta Derm Venereol 1999;79:477 «PMID: 10598768»PubMed
  148. Paul C, Cather J, Gooderham M ym. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015;173:1387-99 «PMID: 26357944»PubMed
  149. Paul CF, Ho VC, McGeown C ym. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6 «PMID: 12542524»PubMed
  150. Pavy S, Constantin A, Pham T ym. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388-95 «PMID: 16626993»PubMed
  151. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009;160:622-8 «PMID: 18945303»PubMed
  152. Rahman P, Gladman DD, Cook RJ ym. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61 «PMID: 9779850»PubMed
  153. Rallis E, Nasiopoulou A, Kouskoukis C ym. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 2005;31:141-5 «PMID: 16223203»PubMed
  154. Ramiro S, Smolen JS, Landewé R ym. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016;75:490-8 «PMID: 26660203»PubMed
  155. Reich K, Langley RG, Papp KA ym. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365:1586-96 «PMID: 22029980»PubMed
  156. Reich K, Nestle FO, Papp K ym. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74 «PMID: 16226614»PubMed
  157. Reich K, Papp KA, Blauvelt A ym. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021;397:487-498 «PMID: 33549193»PubMed
  158. Ritchlin C, Rahman P, Kavanaugh A ym. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9 «PMID: 24482301»PubMed
  159. Ruyssen-Witrand A, Perry R, Watkins C ym. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open 2020;6: «PMID: 32094304»PubMed
  160. Ruzicka T, Sommerburg C, Braun-Falco O ym. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990;126:482-6 «PMID: 2138875»PubMed
  161. Saurat JH, Stingl G, Dubertret L ym. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66 «PMID: 18047523»PubMed
  162. Sbidian E, Chaimani A, Garcia-Doval I ym. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017;12:CD011535 «PMID: 29271481»PubMed
  163. Scarpa R, Peluso R, Atteno M ym. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008;27:823-6 «PMID: 18030515»PubMed
  164. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses =15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014;73:1549-51 «PMID: 24728329»PubMed
  165. Simons N, Degboé Y, Barnetche T ym. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin Exp Rheumatol 2020;38:508-515 «PMID: 31969228»PubMed
  166. Smolen JS, Mease P, Tahir H ym. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis 2020;79:1310-1319 «PMID: 32660977»PubMed
  167. Sterry W, Ortonne JP, Kirkham B ym. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147 «PMID: 20124563»PubMed
  168. Strand V, Elaine Husni M, Betts KA ym. Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis. BMC Rheumatol 2018;2:3 «PMID: 30886954»PubMed
  169. Strober BE, Crowley JJ, Yamauchi PS ym. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:661-8 «PMID: 21574984»PubMed
  170. Thaçi D, Blauvelt A, Reich K ym. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015;73:400-9 «PMID: 26092291»PubMed
  171. Thaçi D, Ortonne JP, Chimenti S ym. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010;163:402-11 «PMID: 20377585»PubMed
  172. Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003;207:166-72 «PMID: 12920367»PubMed
  173. Tyring S, Gordon KB, Poulin Y ym. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26 «PMID: 17576937»PubMed
  174. Tyring S, Gottlieb A, Papp K ym. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35 «PMID: 16399150»PubMed
  175. van de Kerkhof PC, Segaert S, Lahfa M ym. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-85 «PMID: 18673365»PubMed
  176. van de Kerkhof PC, van der Valk PG, Swinkels OQ ym. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006;155:800-7 «PMID: 16965431»PubMed
  177. van Lümig PP, Driessen RJ, Kievit W ym. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013;68:57-63 «PMID: 22846689»PubMed
  178. van Lümig PP, van de Kerkhof PC, Boezeman JB ym. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol 2013;27:593-600 «PMID: 22416818»PubMed
  179. Vilarrasa E, Notario J, Bordas X ym. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol 2016;74:1066-72 «PMID: 27004803»PubMed
  180. Warren RB, Smith CH, Yiu ZZN ym. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015;135:2632-2640 «PMID: 26053050»PubMed
  181. Wilsdon TD, Whittle SL, Thynne TR ym. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev 2019;1:CD012722 «PMID: 30656673»PubMed
  182. Young EW, Ellis CN, Messana JM ym. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994;46:1216-22 «PMID: 7861719»PubMed
  183. Zweegers J, van den Reek JM, van de Kerkhof PC ym. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol 2016;175:340-7 «PMID: 26989852»PubMed
Artikkelin tunnus: nix02812 (050.062)
© 2024 Suomalainen Lääkäriseura Duodecim

Käypä hoito -suositus

Anna palautetta
Linkkien värikoodit